PERFOROMIST

Formoterol

PERFOROMIST

LABA NEB

Formoterol fumarate · Mylan Specialty (Viatris)

Clinical Reference

Active Medication & Mechanism

Formoterol fumarate LABA
20 mcg per 2 mL unit-dose vial

Long-acting beta2-adrenergic agonist with rapid onset of action (~5 minutes). Relaxes bronchial smooth muscle via beta2-receptor activation and increased intracellular cAMP.

FDA-Approved Dosing by Indication

// approval varies by strength + age

COPD

1/1 approved regimens

Strength	Population	Dose & Frequency	Total Daily	Status
20 mcg/2 mL	Adults (≥18 years)	1 vial (20 mcg) nebulized twice daily (morning and evening, ~12 hours apart) Long-term maintenance treatment of bronchoconstriction in COPD, including chronic bronchitis and emphysema. Maximum daily dose is 40 mcg.	40 mcg	FDA Approved

20 mcg/2 mL FDA Approved

Pop · Adults (≥18 years)

1 vial (20 mcg) nebulized twice daily (morning and evening, ~12 hours apart)

Long-term maintenance treatment of bronchoconstriction in COPD, including chronic bronchitis and emphysema. Maximum daily dose is 40 mcg.

Total · 40 mcg

Asthma

0/1 approved regimens

Strength	Population	Dose & Frequency	Total Daily	Status
Any strength	All patients	—	—	Not Approved Perforomist is NOT indicated for asthma. LABA monotherapy in asthma increases risk of serious asthma-related events.

Any strength Not Approved

Pop · All patients

—

Total · — Perforomist is NOT indicated for asthma. LABA monotherapy in asthma increases risk of serious asthma-related events.

Acute Use

0/1 approved regimens

Strength	Population	Dose & Frequency	Total Daily	Status
Any strength	Acute bronchospasm / rescue	—	—	Not Approved Not for acute deterioration of COPD. Use a SABA.

Any strength Not Approved

Pop · Acute bronchospasm / rescue

—

Total · — Not for acute deterioration of COPD. Use a SABA.